 Pharmaceuticals producer and developer competitor activities often are hard to separate and the rapid development in biosciences tend to encourage the labeling of stocks as healthcare. The Covid-19 pandemic is just the most apparent precipitator of terminology generalization. Here our interest is more specific to the investing payoffs than to their scientific genre. 